Why the study?
Does adverse LV remodeling at 6 months (defined as ≥12% increase in both LVESV and LVEDV by CMR) predict worse long-term clinical outcomes in stable reperfused STEMI patients?
Does adverse LV remodeling at 6 months (defined as ≥12% increase in both LVESV and LVEDV by CMR) predict worse long-term clinical outcomes in stable reperfused STEMI patients?
Adverse LV remodeling defined by a ≥12% increase in both LVESV and LVEDV at 6 months post-STEMI identifies patients at higher risk for worse long-term clinical outcomes.
Answers are grounded in this paper and cite their sources.
Adverse LV remodeling by this CMR definition flags higher-risk post-STEMI patients; hypothesis-generating and requires prospective validation before guiding care.
Patients with ST-segment-elevation myocardial infarction developing adverse LV remodeling at 6 months, defined as ≥12% increase in both LVESV and LVEDV by cardiovascular magnetic resonance, was associated with worse long-term clinical outcomes than those with adverse LV remodeling with compensation, reverse LV remodeling, and no LV remodeling, with the latter 3 groups having similar outcomes in a cohort of stable reperfused patients with ST-segment-elevation myocardial infarction. Registration URL: http://www.clinicaltrials.gov. Unique identifier: NCT02072850.
No takes yet. Share an insight, caveat, or question.
Bulluck et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: